ATE519480T1 - Konzentrierte flüssige schilddrüsenhormonzusammensetzung - Google Patents

Konzentrierte flüssige schilddrüsenhormonzusammensetzung

Info

Publication number
ATE519480T1
ATE519480T1 AT07703665T AT07703665T ATE519480T1 AT E519480 T1 ATE519480 T1 AT E519480T1 AT 07703665 T AT07703665 T AT 07703665T AT 07703665 T AT07703665 T AT 07703665T AT E519480 T1 ATE519480 T1 AT E519480T1
Authority
AT
Austria
Prior art keywords
thyroid hormone
concentrated liquid
composition
hormone composition
treat
Prior art date
Application number
AT07703665T
Other languages
English (en)
Inventor
Atimad Gaugain-Hamidi
Cecile Pierres
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Application granted granted Critical
Publication of ATE519480T1 publication Critical patent/ATE519480T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07703665T 2006-01-06 2007-01-05 Konzentrierte flüssige schilddrüsenhormonzusammensetzung ATE519480T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75677706P 2006-01-06 2006-01-06
EP06100133 2006-01-06
PCT/EP2007/050107 WO2007077252A1 (en) 2006-01-06 2007-01-05 Concentrated liquid thyroid hormone composition

Publications (1)

Publication Number Publication Date
ATE519480T1 true ATE519480T1 (de) 2011-08-15

Family

ID=37833322

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07703665T ATE519480T1 (de) 2006-01-06 2007-01-05 Konzentrierte flüssige schilddrüsenhormonzusammensetzung

Country Status (7)

Country Link
US (1) US8318712B2 (de)
EP (1) EP1973524B1 (de)
JP (1) JP5173832B2 (de)
KR (1) KR20080083685A (de)
AT (1) ATE519480T1 (de)
CA (1) CA2634993A1 (de)
WO (1) WO2007077252A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1395454B1 (it) * 2009-03-24 2012-09-21 Altergon Sa Composizioni e forme farmaceutiche per somministrazione orale di ormoni tiroidei in grado di contrastare l'azione di agenti sequestranti nel tratto gastrointestinale
DK2683361T3 (da) 2011-03-10 2016-02-01 Emp Pharma Gmbh Fremgangsmåde til fremstilling af en levothyroxinopløsning
US10328152B2 (en) 2011-06-16 2019-06-25 Nayan Patel Method for stabilization and delivery of therapeutic molecules
WO2013033194A1 (en) 2011-08-30 2013-03-07 Fresenius Kabi Usa, Llc Levothyroxine formulations
DE102013017917A1 (de) * 2013-10-26 2015-04-30 Michael Raschke L-Thyrogal
EP3315966A4 (de) * 2015-06-29 2018-11-14 Fujirebio Inc. Schilddrüsenhormonstandardlösung
US11154498B2 (en) 2015-07-22 2021-10-26 Leiutis Pharmaceuticals Pvt. Ltd. Stabilized liquid formulation of levothyroxine
US11364196B2 (en) * 2015-11-04 2022-06-21 Leiutis Pharmaceuticals Pvt. Ltd. Levothyroxine formulations for oral use
NL2017110B1 (en) 2016-07-05 2018-01-12 Emp Levo Gmbh Methods for the preparation of a levothyroxine solution
EP3311844A1 (de) 2016-10-18 2018-04-25 Altergon S.A. Hochstabile verpackte lösungen von t4-schilddrüsenhormon
US9782376B1 (en) * 2016-12-01 2017-10-10 Fresenius Kabi Usa Llc Levothyroxine liquid formulations
WO2019023791A1 (en) * 2017-07-31 2019-02-07 Apollo Pharmaceuticals Inc. LEVOTHYROXIN FORMULATIONS
US11241382B2 (en) 2019-03-01 2022-02-08 Altergon Sa Administration regimen of compositions of T4 thyroid hormone with high oral absorption
WO2021100063A1 (en) 2019-11-22 2021-05-27 Wockhardt Limited Oral film composition comprising levothyroxine
EP4704805A2 (de) * 2023-05-02 2026-03-11 Labomed Pharmaceutical Company S.A. Orale lösung mit liothyronin-natrium

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
GB9012663D0 (en) 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
GB9401891D0 (en) 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
BR9611306A (pt) * 1995-11-14 1999-12-28 Knoll Pharmaceuticals Co Preparação farmacêutica e, composto farmacêutica estável.
HUT75956A (en) * 1995-11-29 1997-05-28 Cyclolab Pharmaceutical composition containing thyroxine
MXPA05002728A (es) * 2002-09-13 2005-07-25 Cydex Inc Capsulas que contienen composiciones de relleno acuoso estabilizadas con ciclodextrina derivada.
GB0316206D0 (en) * 2003-07-10 2003-08-13 Glaxo Group Ltd Pharmaceutical formulation

Also Published As

Publication number Publication date
US20090270507A1 (en) 2009-10-29
EP1973524B1 (de) 2011-08-10
JP5173832B2 (ja) 2013-04-03
CA2634993A1 (en) 2007-07-12
JP2009522335A (ja) 2009-06-11
WO2007077252A1 (en) 2007-07-12
EP1973524A1 (de) 2008-10-01
KR20080083685A (ko) 2008-09-18
US8318712B2 (en) 2012-11-27

Similar Documents

Publication Publication Date Title
HN2006000971A (es) Metodos para preparar composiciones o formas de dosificacion que comprenden un agonista grp119 que tiene el efecto de un secretagogo glp-1
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
GT200800151A (es) Inhibidores de 11-beta-hsd1
MX2009006481A (es) Derivados de imidazol 1-sustituidos, y su uso como inhibidores de la sintasa de aldosterona.
EA200970175A1 (ru) Способы и композиции для ингибирования ангиогенеза
CR10748A (es) Compuesto de indol
EP2279244A4 (de) Verfahren und zusammensetzungen zur oralen verabreichung von proteinen
CL2008003653A1 (es) Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
MX2010006823A (es) Metodos para el tratamiento de la gota.
MA32934B1 (fr) Combinaisons inhibitrices hsp90
EP2506717A4 (de) Verfahren zur verwendung von dopamin-wiederaufnahmehemmern und ihren analogen zur behandlung von diabetessymptomen und zur verzögerung oder verhinderung von mit diabetes assoziierten erkrankungen
BRPI0712631B8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
EA200970580A1 (ru) Таннат разагилина
MX356584B (es) Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
MA32981B1 (fr) Regime posologique pour un agoniste du recepteur s1p
CL2008001896A1 (es) 3-dihalometil-1-metil-1h-pirazol-4-carbaldehidos; su proceso de preparacion usando un intermediario de hidrazona, que reacciona con un agente de vilsmeier; y el derivado de hidrazona usado.
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
EA201200917A1 (ru) Пролекарства ингибиторов плазменного калликреина
NO20083143L (no) Fremgangsmate og arrangement for innmating av kjemikalier i en prosesstrom
WO2007098099A3 (en) Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor
WO2007143086A3 (en) Delivery method
WO2009124294A3 (en) Pharmaceutical compositions for binding sphingosine-1-phosphate
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
ATE458480T1 (de) Hexahydro-cyclooctyl-pyrazol-cannabinoid- modulatoren
EA201000392A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties